Vaxcyte (PCVX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec8

Vaxcyte Inc. Initiates OPUS Phase 3 Clinical Trial for VAX-31 Pneumococcal Vaccine

12:00

Nov20

Mizuho Analyst Maintains Buy Rating on Vaxcyte

21:01

Nov10

BTIG Analyst Thomas Shrader Maintains Buy Rating on Vaxcyte with $85 Target Price

12:12

Nov5

Analyst Maintains Strong Buy Rating on Vaxcyte Stock

12:02

Vaxcyte released FY2025 Q3 earnings on November 4 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.5626 (forecast USD -1.31)

04:00

Vaxcyte released FY2025 9 Months earnings on November 4, 2025 (EST), actual revenue USD 0, actual EPS USD -3.8242

04:00

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -212.83 M, EPS -1.5626

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -166.57 M, EPS -1.2244

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -140.72 M, EPS -1.037

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change